Skip to main content

Advertisement

SpringerLink
Log in

Second Malignancies after Hematopoietic Stem Cell Transplantation

  • Leukemia (PH Wiernik, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Second malignancies are a rare but well-defined late complication after autologous and allogeneic hematopoietic stem-cell transplantation (SCT). Solid malignancies occur in up to 15% of patients 15 years after SCT with myeloablative conditioning, with no plateau in the incidence rates. They are responsible for 5–10% of late deaths after SCT. The incidence is increased with advanced age at SCT. The major risk factors are the use of total body irradiation, which is associated with adenocarcinomas and with chronic graft-versus-host disease which is associated with squamous cell cancers. There is less data on the incidence of second malignancies after reduced-intensity conditioning, but it may not be lower. The types of solid tumors reported in excess include melanoma and other skin cancers; cancers of the oral cavity and head and neck, brain, liver, uterine cervix, thyroid, breast, lung; and possibly gastrointestinal cancers. Therapy-related myeloid neoplasms (t-MN) are more common after autologous SCT and may be related mostly to pre-transplant therapies. Post-transplant lymphoproliferative disease is donor-cell-derived lymphoma that is more common after allogeneic SCT with T-cell depletion or intensive immune-suppression state. Second malignancies are most often treated similarly to the standard therapy for similar malignancies. Lifelong cancer screening and prevention interventions are required for all transplantation survivors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Gooley TA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. •• Shimoni A. Second malignancies after allogeneic stem cell transplantation with reduced-intensity conditioning: is the incidence reduced? Biol Blood Marrow Transplant. 2014;20(11):1669–70. This is our opinion of second malignancies after RIC is based on our single-center analysis. The records of 931 consecutive patients given allogeneic SCT with MAC (n = 257), RIC (n = 449) or RTC (n = 225), in a single institution over a 13-year period, were reviewed. Twenty-seven patients had secondary malignancy, diagnosed a median of 43 months (7 months–11.5 years) after SCT. This study is very important because it showed that the risk of secondary malignancies is not reduced and is even possibly increased in the era of fludarabine-based RIC/RTC.

    Article  PubMed  Google Scholar 

  3. Majhail NS, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(3):348–71.

    Article  PubMed  Google Scholar 

  4. • Ringden O, et al. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014;20(11):1777–84. In this study was examined risk of second solid cancers after allo-SCT using RIC/NMC for recipients with leukemia/MDS (n = 2833) and lymphoma (n = 1436) between 1995 and 2006. In addition, RIC/NMC recipients 40 to 60 years of age (n = 2138) were compared with patients of the same age receiving myeloablative conditioning (MAC, n = 6428). In this study the overall risks of second solid cancers in RIC/NMC recipients were similar to the general population, although there is an increased risk of cancer at some sites.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Armenian SH, et al. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the bone marrow transplant survivor study (BMTSS) and childhood cancer survivor study (CCSS). Blood. 2011;118(5):1413–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. •• Chow EJ, et al. Morbidity and mortality differences between hematopoietic cell transplantation survivors and other cancer survivors. J Clin Oncol. 2017;35(3):306–13. This study compared the risks of serious health outcomes among hematopoietic SCT survivors (n = 1792) and a matched population of patients with cancer who did not undergo SCT (n = 5455) and the general population (n = 16,340). History of SCT was associated with late morbidity and mortality among cancer survivors, in particular, high rates of late respiratory and infectious complications. Interesting, during the median follow-up of 7 years the two groups had similar risks of circulatory complications and second cancers.

    Article  PubMed  Google Scholar 

  7. •• Inamoto Y, et al. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50(8):1013–23. A working group was established through the CIBMTR and the EBMT with the goal to facilitate implementation of cancer screening appropriate to SCT recipients. The working group reviewed guidelines and methods for cancer screening applicable to the general population and reviewed the incidence and risk factors for secondary cancers after SCT. A consensus approach was used to establish recommendations for individual secondary cancers. This study is the guidelines to help clinicians in providing screening and preventive care for secondary cancers among SCT recipients.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Wingard JR, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29(16):2230–9.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Majhail NS, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011;117(1):316–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Rizzo JD, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113(5):1175–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Atsuta Y, et al. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. Ann Oncol. 2014;25(2):435–41.

    Article  CAS  PubMed  Google Scholar 

  12. Yokota A, et al. Secondary solid tumors after allogeneic hematopoietic SCT in Japan. Bone Marrow Transplant. 2012;47(1):95–100.

    Article  CAS  PubMed  Google Scholar 

  13. Sureda A, et al. Autologous stem-cell transplantation for Hodgkin’s disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19(5):1395–404.

    Article  CAS  PubMed  Google Scholar 

  14. Smeland KB, et al. A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma. Br J Haematol. 2016;173(3):432–43.

    Article  CAS  PubMed  Google Scholar 

  15. Forrest DL, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin’s lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol. 2005;23(31):7994–8002.

    Article  CAS  PubMed  Google Scholar 

  16. Goodman KA, et al. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin’s lymphoma. J Clin Oncol. 2008;26(32):5240–7.

    Article  PubMed  Google Scholar 

  17. Czyz A, et al. Second malignancies after autologous hematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma—characteristics and risk factor analysis. Contemp Oncol (Pozn). 2013;17(2):200–4.

    Google Scholar 

  18. Miller JS, et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood. 1994;83(12):3780–6.

    CAS  PubMed  Google Scholar 

  19. Del Canizo M, et al. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation. Haematologica. 2000;85(4):403–9.

    PubMed  Google Scholar 

  20. Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 2000;95(11):3273–9.

    CAS  PubMed  Google Scholar 

  21. Friedman DL, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood. 2008;111(2):939–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Micallef IN, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000;18(5):947–55.

    Article  CAS  PubMed  Google Scholar 

  23. Brown JR, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23(10):2208–14.

    Article  CAS  PubMed  Google Scholar 

  24. Akpek G, et al. Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol. 2001;19(23):4314–21.

    Article  CAS  PubMed  Google Scholar 

  25. Tarella C, et al. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011;29(7):814–24.

    Article  CAS  PubMed  Google Scholar 

  26. Curtis RE, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336(13):897–904.

    Article  CAS  PubMed  Google Scholar 

  27. Witherspoon RP, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med. 1989;321(12):784–9.

    Article  CAS  PubMed  Google Scholar 

  28. Themeli M, et al. Alloreactive microenvironment after human hematopoietic cell transplantation induces genomic alterations in epithelium through an ROS-mediated mechanism: in vivo and in vitro study and implications to secondary neoplasia. Leukemia. 2010;24(3):536–43.

    Article  CAS  PubMed  Google Scholar 

  29. Savani BN, et al. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation--implications for screening and HPV vaccination. Biol Blood Marrow Transplant. 2008;14(9):1072–5.

    Article  PubMed  PubMed Central  Google Scholar 

  30. van Leeuwen FE, et al. Leukemia risk following Hodgkin’s disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol. 1994;12(5):1063–73.

    Article  PubMed  Google Scholar 

  31. Le Deley MC, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d’Oncologie Pediatrique. J Clin Oncol. 2003;21(6):1074–81.

    Article  PubMed  Google Scholar 

  32. Shimoni A, et al. Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced. Leukemia. 2013;27(4):829–35.

    Article  CAS  PubMed  Google Scholar 

  33. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41(2):93–103.

    Article  CAS  PubMed  Google Scholar 

  34. Sacchi S, et al. Secondary malignancies after treatment for indolent non-Hodgkin’s lymphoma: a 16-year follow-up study. Haematologica. 2008;93(3):398–404.

    Article  PubMed  Google Scholar 

  35. Tam CS, et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica. 2006;91(11):1546–50.

    CAS  PubMed  Google Scholar 

  36. Smith MR, et al. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood. 2011;118(13):3525–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Majhail NS. Secondary cancers following allogeneic hematopoietic cell transplantation in adults. Br J Haematol. 2011;154(3):301–10.

    Article  PubMed  Google Scholar 

  38. Baker KS, et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21(7):1352–8.

    Article  PubMed  Google Scholar 

  39. Leisenring W, et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol. 2006;24(7):1119–26.

    Article  PubMed  Google Scholar 

  40. Schwartz JL, et al. Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. Radiat Res. 2009;171(2):155–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Curtis RE, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005;105(10):3802–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Bhatia S, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001;19(2):464–71.

    Article  CAS  PubMed  Google Scholar 

  43. Cohen A, et al. Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT late effects working party study. J Clin Oncol. 2007;25(17):2449–54.

    Article  PubMed  Google Scholar 

  44. •• Ehrhardt MJ, et al. Survival of patients who develop solid tumors following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51(1):83–8. Most reports address risk factors for second cancers after hematopoietic SCT; however, outcomes after secondary solid cancer development are incompletely described. This study estimated survival probabilities for transplant recipients dependent on secondary solid cancer subtype. Overall survival varied by secondary cancer type. Secondary cancer was the cause of death in most patients who died following development of melanoma, central nervous system, oral cavity, thyroid, lung, lower gastrointestinal tract and bone cancers.

    Article  CAS  PubMed  Google Scholar 

  45. Akhtari M, et al. Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients. Cancer Biol Ther. 2013;14(12):1077–88.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Gilliland DG, Gribben JG. Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(1):9–16.

    Article  CAS  PubMed  Google Scholar 

  47. Seshadri T, et al. Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2009;50(3):380–6.

    Article  PubMed  Google Scholar 

  48. Harrison CN, et al. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin’s disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer. 1999;81(3):476–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Pedersen-Bjergaard J, et al. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia. 1997;11(10):1654–60.

    Article  CAS  PubMed  Google Scholar 

  50. Lillington DM, et al. Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin’s lymphoma. J Clin Oncol. 2001;19(9):2472–81.

    Article  CAS  PubMed  Google Scholar 

  51. Abruzzese E, et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood. 1999;94(5):1814–9.

    CAS  PubMed  Google Scholar 

  52. Amigo ML, et al. Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS. Bone Marrow Transplant. 1999;23(10):997–1002.

    Article  CAS  PubMed  Google Scholar 

  53. Laurenti L, et al. Secondary myelodysplastic syndromes following peripheral blood stem cell transplantation: morphological, cytogenetic and clonality evaluation and the limitation of FAB criteria. Bone Marrow Transplant. 2000;26(2):241–2.

    Article  CAS  PubMed  Google Scholar 

  54. Keung YK, et al. Possible role of engraftment syndrome and autologous graft-versus-host disease in myelodysplastic syndrome after autologous stem cell transplantations: retrospective analysis and review of the literature. Clin Lymphoma Myeloma Leuk. 2010;10(2):129–33.

    Article  PubMed  Google Scholar 

  55. Traweek ST, et al. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin’s disease and non-Hodgkin’s lymphoma. Blood. 1994;84(3):957–63.

    CAS  PubMed  Google Scholar 

  56. Krishnan A, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95(5):1588–93.

    CAS  PubMed  Google Scholar 

  57. Darrington DL, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12(12):2527–34.

    Article  CAS  PubMed  Google Scholar 

  58. Milligan DW, et al. Secondary leukemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT lymphoma and late effects working parties. European Group for Blood and Marrow Transplantation. Br J Haematol. 1999;106(4):1020–6.

    Article  CAS  PubMed  Google Scholar 

  59. Hosing C, et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. Ann Oncol. 2002;13(3):450–9.

    Article  CAS  PubMed  Google Scholar 

  60. Metayer C, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003;101(5):2015–23.

    Article  CAS  PubMed  Google Scholar 

  61. Armitage JO, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. J Clin Oncol. 2003;21(5):897–906.

    Article  PubMed  Google Scholar 

  62. Bhatia S, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87(9):3633–9.

    CAS  PubMed  Google Scholar 

  63. Majhail NS. Old and new cancers after hematopoietic-cell transplantation. Hematol Am Soc Hematol Educ Program. 2008;142–9.

  64. Landgren O, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992–5001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Curtis RE, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94(7):2208–16.

    CAS  PubMed  Google Scholar 

  66. Heslop HE, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. • Styczynski J, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7):803–11. EBV-related PTLDs are recognized as a significant cause of morbidity and mortality in patients undergoing hematopoietic SCT. To better define current understanding of PTLD in stem cell transplant patients, and to improve its diagnosis and management, a working group of the Sixth European Conference on Infections in Leukemia 2015 reviewed the literature, graded the available quality of evidence, and developed evidence-based recommendations for diagnosis, prevention, prophylaxis and therapy of PTLDs exclusively in the stem cell transplant setting.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Sanz J, et al. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transplant. 2014;49(3):397–402.

    Article  CAS  PubMed  Google Scholar 

  69. Kanakry JA, et al. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2013;19(10):1514–7.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Courville EL, et al. EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations. Mod Pathol. 2016;29(10):1200–11.

    Article  CAS  PubMed  Google Scholar 

  71. Xuan L, et al. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation. Transplantation. 2013;96(6):560–6.

    Article  CAS  PubMed  Google Scholar 

  72. Fox CP, et al. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. Bone Marrow Transplant. 2014;49(2):280–6.

    Article  CAS  PubMed  Google Scholar 

  73. Nash RA, et al. Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant. 2003;9(9):583–91.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Uhlin M, et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014;99(2):346–52.

    Article  PubMed  PubMed Central  Google Scholar 

  75. van Esser JW, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99(12):4364–9.

    Article  PubMed  Google Scholar 

  76. Ahmad I, et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation. 2009;87(8):1240–5.

    Article  CAS  PubMed  Google Scholar 

  77. Stevens SJ, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97(5):1165–71.

    Article  CAS  PubMed  Google Scholar 

  78. Omar H, et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis. 2009;11(5):393–9.

    Article  CAS  PubMed  Google Scholar 

  79. Styczynski J, et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013;57(6):794–802.

    Article  CAS  PubMed  Google Scholar 

  80. van der Velden WJ, et al. Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab. Bone Marrow Transplant. 2013;48(11):1465–71.

    Article  PubMed  Google Scholar 

  81. Worth A, et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol. 2011;155(3):377–85.

    Article  CAS  PubMed  Google Scholar 

  82. Cesaro S, et al. A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation. Transplantation. 2010;89(12):1533–40.

    Article  CAS  PubMed  Google Scholar 

  83. Doubrovina E, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119(11):2644–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Schouten HC, et al. Large-cell anaplastic non-Hodgkin’s lymphoma originating in donor cells after allogenic bone marrow transplantation. Br J Haematol. 1995;91(1):162–6.

    Article  CAS  PubMed  Google Scholar 

  85. Rowlings PA, et al. Increased incidence of Hodgkin’s disease after allogeneic bone marrow transplantation. J Clin Oncol. 1999;17(10):3122–7.

    Article  CAS  PubMed  Google Scholar 

  86. Hertenstein B, et al. Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2005;90(7):969–75.

    PubMed  Google Scholar 

  87. Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant. 2011;17(6):771–89.

    Article  PubMed  Google Scholar 

  88. Rizzo JD, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006;12(2):138–51.

    Article  PubMed  Google Scholar 

  89. Saslow D, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75–89.

    Article  PubMed  Google Scholar 

  90. Chao NJ, et al. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin’s disease. J Clin Oncol. 1991;9(9):1575–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel

    Ivetta Danylesko MD & Avichai Shimoni MD

  2. Sacker school of medicine, Tel-Aviv University, Tel-Aviv, Israel

    Ivetta Danylesko MD & Avichai Shimoni MD

Authors
  1. Ivetta Danylesko MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Avichai Shimoni MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Avichai Shimoni MD.

Ethics declarations

Conflict of Interest

The authors declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Leukemia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Danylesko, I., Shimoni, A. Second Malignancies after Hematopoietic Stem Cell Transplantation. Curr. Treat. Options in Oncol. 19, 9 (2018). https://doi.org/10.1007/s11864-018-0528-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-018-0528-y

Keywords

Search

Navigation